Related Experiment Video
Updated: Jul 23, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Effects of platelet inhibition on myocardial ischaemia
Insights
This study suggests platelets may contribute to myocardial ischemia. Ticlopidine, an anti-platelet drug, significantly reduced chest pain and S-T segment depression in patients with coronary artery disease.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Platelets are implicated in cardiovascular diseases.
- Myocardial ischemia is a condition of reduced blood flow to the heart muscle.
- Understanding the role of platelets in ischemia is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of platelets in the pathogenesis of myocardial ischemia.
- To evaluate the effect of ticlopidine, a platelet aggregation inhibitor, on patients with coronary artery disease and angina pectoris.
Main Methods:
- A single-blind study involving 10 patients with coronary artery disease.
- Patients received three treatments: placebo, ticlopidine (500 mg for 4 weeks), and placebo.
- Ambulatory S-T segment monitoring and recording of chest pain frequency were conducted post-treatment.
Main Results:
- Ticlopidine treatment significantly reduced reported chest pain frequency.
- Ticlopidine significantly decreased the number of S-T segment depression episodes.
- The reduction in S-T segment depression was notable during periods without increased heart rate and at night.
Conclusions:
- Platelets may play a significant role in the pathogenesis of myocardial ischemia.
- Ticlopidine demonstrates potential therapeutic benefits in managing ischemic events.
- Further research is needed to elucidate the exact mechanisms involved.
Abstract:
Ticlopidine, a potent inhibitor of platelet aggregation, was found to have no direct effects on coronary resistance or coronary flow in 5 dogs. To determine whether platelets can be implicated in the pathogenesis of myocardial ischaemia the effects of this drug were studied in 10 patients with proven coronary-artery disease and daily angina pectoris. Each underwent three single-blind treatments: (a) placebo for 2 weeks; (b) ticlopidine 500 mg for 4 weeks; and (c) placebo for 2 weeks. For 4 days after the end of each treatment ambulatory S-T segments were monitored and a record was kept of the reported frequency of chest pain. 4 weeks' treatment with ticlopidine resulted in a significant fall in both the reported frequency of chest pain and the number of episodes of S-T segment depression. This effect was most striking in those episodes of S-T segment depression that occurred without increase in heart rate and in the middle of the night. Thus, although the exact mechanisms remain to be clarified this study suggests that platelets may play an important part in the pathogenesis of myocardial ischaemia.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:21Myocarditis I: Introduction
01:14Myocarditis III: Medical Management
01:26Coronary Artery Disease II: Pathophysiology